César Augusto
Rodríguez Sánchez
Profesor Asociado CC. Salud
Hospital Universitario de Salamanca
Salamanca, EspañaPublications in collaboration with researchers from Hospital Universitario de Salamanca (71)
2024
-
Cáncer de mama
Oncología clínica (Arán Ediciones), pp. 203-226
-
Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union
Future oncology (London, England), Vol. 20, Núm. 13, pp. 821-832
-
Tratamiento Sistémico del Cáncer (I): Quimioterapia
Oncología clínica (Arán Ediciones), pp. 73-87
-
Tratamiento Sistémico del Cáncer (II): hormonoterapia
Oncología clínica (Arán Ediciones), pp. 89-99
-
Tratamiento Sistémico del Cáncer (III): inmunoterapia y terapias biológicas
Oncología clínica (Arán Ediciones), pp. 101-116
-
Urgencias en oncología
Oncología clínica (Arán Ediciones), pp. 129-145
2023
-
Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study
Cancers, Vol. 15, Núm. 5
-
Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk
Cells, Vol. 12, Núm. 15
2022
2021
-
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
European Journal of Cancer, Vol. 156, pp. 70-82
-
Value of skin tests for managing allergic hypersensitivity reactions to platinum compounds
International Journal of Clinical Pharmacy, Vol. 43, Núm. 4, pp. 1123-1127
2020
-
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428
-
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
Breast, Vol. 54, pp. 286-292
-
Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)
European Journal of Cancer Care, Vol. 29, Núm. 4
-
Stromal SNAI2 is required for ERBB2 breast cancer progression
Cancer Research, Vol. 80, Núm. 23, pp. 5216-5230
-
The economic burden of metastatic breast cancer in Spain
European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24
2019
-
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Aging, Vol. 11, Núm. 9, pp. 2874-2888
-
Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer
Journal of Clinical Medicine, Vol. 8, Núm. 12
-
Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study
Clinical Breast Cancer, Vol. 19, Núm. 2, pp. 105-112
-
The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin
Frontiers in Oncology, Vol. 9, Núm. MAR